{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:53:00Z","timestamp":1793757180501,"version":"4.6.1"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T00:00:00Z","timestamp":1547164800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sponsored Research Agreement from Boehringer Ingelheim RCV, Vienna, Austria"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13046-018-0999-5","type":"journal-article","created":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T07:22:29Z","timestamp":1547191349000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Therapeutic impact of Nintedanib with paclitaxel and\/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer"],"prefix":"10.1186","volume":"38","author":[{"given":"Elaine","family":"Reguera-Nu\u00f1ez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Hilberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Kerbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,11]]},"reference":[{"key":"999_CR1","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification on human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750\u201367.","journal-title":"J Clin Invest"},{"key":"999_CR2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.4048\/jbc.2016.19.3.223","volume":"19","author":"SG Ahn","year":"2016","unstructured":"Ahn SG, Jun Kim SJ, Kim C, Jeong J. Molecular classification of triple-negative breast Cancer. J Breast Cancer. 2016;19:223\u201330.","journal-title":"J Breast Cancer"},{"key":"999_CR3","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ctrv.2017.11.003","volume":"62","author":"A Lee","year":"2018","unstructured":"Lee A, Djamgoz MBA. Triple negative breast cancer: emerging therapeutic modalities and novel combination therapies. Cancer Treat Rev. 2018;62:110\u201322.","journal-title":"Cancer Treat Rev"},{"key":"999_CR4","doi-asserted-by":"publisher","unstructured":"Rida P, Ogden A, Ellis IO, Varga Z, Wolff AC, Traina TA, et al. First international TNBC conference meeting report. Breast Cancer Res Treat. 2018; doi.org\/\n                    https:\/\/doi.org\/10.1007\/s10549-018-4692-3\n                    \n                  .","DOI":"10.1007\/s10549-018-4692-3"},{"key":"999_CR5","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13:674\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"999_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/cncr.28914","volume":"121","author":"VG Abramson","year":"2015","unstructured":"Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA. Subtyping of triple-negative breast cancer: implications for therapy. Cancer. 2015;121:8\u201316.","journal-title":"Cancer"},{"key":"999_CR7","first-page":"59","volume":"28","author":"S Hurvitz","year":"2016","unstructured":"Hurvitz S, Mead M. Triple-negative breast cancer: advancements in characterization and treatment approach. Curr Opin Obstet Gynecol. 2016;28:59\u201369.","journal-title":"Curr Opin Obstet Gynecol"},{"key":"999_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/BF00666035","volume":"36","author":"N Ferrara","year":"1995","unstructured":"Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat. 1995;36:127\u201337.","journal-title":"Breast Cancer Res Treat"},{"key":"999_CR9","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197108122850711","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman J. Tumor angiogenesis: therapeutic implications. New Engl J Med. 1971;285:1182\u20136.","journal-title":"New Engl J Med."},{"key":"999_CR10","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S0140-6736(15)01088-0","volume":"388","author":"GC Jayson","year":"2016","unstructured":"Jayson GC, Kerbel R, Ellis LM, Harris AL. Antiangiogenic therapy in oncology: current status and future directions. Lancet. 2016;388:518\u201329.","journal-title":"Lancet"},{"key":"999_CR11","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus Bevacizumab versus paclitaxel alone for metastatic breast cancer. New Engl J Med. 2007;357:2666\u201376.","journal-title":"New Engl J Med."},{"key":"999_CR12","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/S1470-2045(14)70444-9","volume":"15","author":"J Gligorov","year":"2014","unstructured":"Gligorov J, Doval D, Bines J, Alba E, Cortes P, Pierga JY, et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1351\u201360.","journal-title":"Lancet Oncol."},{"key":"999_CR13","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1200\/JCO.2007.15.7636","volume":"27","author":"A Hauschild","year":"2009","unstructured":"Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009;27:2823\u201330.","journal-title":"J Clin Oncol"},{"key":"999_CR14","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1200\/JCO.2009.26.1321","volume":"28","author":"G Scagliotti","year":"2010","unstructured":"Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, et al. Phase III study of carboplatin and paclitaxel alone or with Sorafenib in advanced non\u2013small-cell lung Cancer. J Clin Oncol. 2010;28:1835\u201342.","journal-title":"J Clin Oncol"},{"key":"999_CR15","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1470-2045(10)70132-7","volume":"11","author":"RS Herbst","year":"2010","unstructured":"Herbst RS, Sun Y, Eberhardt WE, Germonpr\u00e9 P, Saijo N, Zhou C, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2010;11:619\u201326.","journal-title":"Lancet Oncol"},{"key":"999_CR16","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1200\/JCO.2010.29.5717","volume":"29","author":"RH Boer de","year":"2011","unstructured":"de Boer RH, Arrieta \u00d3, Yang CH, Gottfried M, Chan V, Raats J, et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2011;29:1067\u201374.","journal-title":"J Clin Oncol"},{"key":"999_CR17","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1200\/JCO.2010.29.4496","volume":"29","author":"JR Hecht","year":"2011","unstructured":"Hecht JR, Trarbach T, Hainsworth JD, Major P, J\u00e4ger E, Wolff RA, et al. Randomized, placebo-controlled, phase II study of first-line oxaliplatin-based chemotherapy plus PTK787\/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol. 2011;29:1997\u20132003.","journal-title":"J Clin Oncol"},{"key":"999_CR18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.clbc.2011.03.005","volume":"11","author":"NJ Robert","year":"2011","unstructured":"Robert NJ, Saleh MN, Paul D, Generali D, Gressot L, Copur MS, et al. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast Cancer: a phase III, randomized. Open-Label Trial Clin Breast Cancer. 2011;11:82\u201392.","journal-title":"Open-Label Trial Clin Breast Cancer"},{"key":"999_CR19","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1200\/JCO.2011.35.7376","volume":"30","author":"J Bergh","year":"2012","unstructured":"Bergh J, Bondarenko IM, Lichinitser MR, Liljegren A, Greil R, Voytko NL, et al. First-line treatment of advanced breast Cancer with Sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol. 2012;30:921\u20139.","journal-title":"J Clin Oncol"},{"key":"999_CR20","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1200\/JCO.2012.42.1529","volume":"31","author":"KT Flaherty","year":"2013","unstructured":"Flaherty KT, Lee SJ, Zhao F, Schuchter LM, Flaherty L, Kefford R, et al. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol. 2013;31:373\u20139.","journal-title":"J Clin Oncol"},{"key":"999_CR21","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1200\/JCO.2011.39.7646","volume":"30","author":"LG Paz-Ares","year":"2012","unstructured":"Paz-Ares LG, Biesma B, Heigener D, von Pawel J, Eisen T, Bennouna J, et al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine\/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol. 2012;30:3084\u201392.","journal-title":"J Clin Oncol"},{"key":"999_CR22","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1200\/JCO.2011.41.4987","volume":"30","author":"GV Scagliotti","year":"2012","unstructured":"Scagliotti GV, Vynnychenko I, Park K, Ichinose Y, Kubota K, Blackhall F, et al. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin\/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol. 2012;30:2829\u201336.","journal-title":"J Clin Oncol"},{"key":"999_CR23","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1200\/JCO.2012.42.5355","volume":"30","author":"HJ Schmoll","year":"2012","unstructured":"Schmoll HJ, Cunningham D, Sobrero A, Karapetis CS, Rougier P, Koski SL, et al. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol. 2012;30:3588\u201395.","journal-title":"J Clin Oncol"},{"key":"999_CR24","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1038\/bjc.2012.100","volume":"1006","author":"JH Yi","year":"2012","unstructured":"Yi JH, Lee J, Lee J, Park SH, Park JO, Yim DS, et al. Randomized phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. Br J Cancer. 2012;1006:1469\u201374.","journal-title":"Br J Cancer"},{"key":"999_CR25","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1200\/JCO.2012.45.1930","volume":"31","author":"A Carrato","year":"2013","unstructured":"Carrato A, Swieboda-Sadlej A, Staszewska-Skurczynska M, Lim R, Roman L, Shparyk Y, et al. Fluorouracil, Leucovorin, and irinotecan plus either Sunitinib or placebo in metastatic colorectal Cancer: a randomized, Phase III Trial. J Clin Oncol. 2013;31:1341\u20137.","journal-title":"J Clin Oncol"},{"key":"999_CR26","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1200\/JCO.2012.43.3391","volume":"31","author":"JP Crown","year":"2013","unstructured":"Crown JP, Di\u00e9ras V, Staroslawska E, Yardley DA, Bachelot T, Davidson N, et al. Phase III trial of Sunitinib in combination with Capecitabine versus Capecitabine monotherapy for the treatment of patients with pretreated metastatic breast Cancer. J Clin Oncol. 2013;31:2870\u20138.","journal-title":"J Clin Oncol"},{"key":"999_CR27","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","volume":"15","author":"M Reck","year":"2014","unstructured":"Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15:143\u201355.","journal-title":"Lancet Oncol."},{"key":"999_CR28","doi-asserted-by":"publisher","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","volume":"68","author":"F Hilberg","year":"2008","unstructured":"Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, et al. BIBF 1120: triple Angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68:4774\u201382.","journal-title":"Cancer Res"},{"key":"999_CR29","doi-asserted-by":"publisher","first-page":"3691","DOI":"10.2147\/OTT.S78805","volume":"8","author":"N Awasthi","year":"2015","unstructured":"Awasthi N, Schwarz RE. Profile of nintedanib in the treatment of solid tumors: the evidence to date. Onco Targets Ther. 2015;8:3691\u201301.","journal-title":"Onco Targets Ther"},{"key":"999_CR30","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.lungcan.2015.08.003","volume":"90","author":"M Reck","year":"2015","unstructured":"Reck M, Mellemgaard A, von Pawel J, Gottfried M, Bondarenko I, Cheng Y, et al. Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel. Lung Cancer. 2015;90:267\u201373.","journal-title":"Lung Cancer"},{"key":"999_CR31","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1200\/JCO.2011.36.7771","volume":"30","author":"J Baselga","year":"2012","unstructured":"Baselga J, Segalla JG, Roch\u00e9 H, Del Giglio A, Pinczowski H, Ciruelos EM, et al. Sorafenib in combination with Capecitabine: an Oral regimen for patients with HER2-negative locally advanced or metastatic breast Cancer. J Clin Oncol. 2012;30:1484\u201391.","journal-title":"J Clin Oncol"},{"key":"999_CR32","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/annonc\/mdp506","volume":"21","author":"A Bois du","year":"2010","unstructured":"du Bois A, Huober J, Stopfer P, Pfisterer J, Wimberger P, Loibl S, et al. A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. Ann Oncol. 2010;21:370\u20135.","journal-title":"Ann Oncol"},{"key":"999_CR33","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1093\/annonc\/mdr596","volume":"23","author":"RC Doebele","year":"2012","unstructured":"Doebele RC, Conkling P, Traynor AM, Otterson GA, Zhao Y, Wind S, et al. A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol. 2012;23:2094\u201302.","journal-title":"Ann Oncol"},{"key":"999_CR34","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1038\/bjc.2014.397","volume":"111","author":"M Quintela-Fandino","year":"2014","unstructured":"Quintela-Fandino M, Urruticoechea A, Guerra J, Gil M, Gonzalez-Martin A, Marquez R, et al. Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010\/GEICAM-2010-10 study). Br J Cancer. 2014;111:1060\u20134.","journal-title":"Br J Cancer"},{"key":"999_CR35","doi-asserted-by":"publisher","first-page":"e0164499","DOI":"10.1371\/journal.pone.0164499","volume":"11","author":"C Schliemann","year":"2016","unstructured":"Schliemann C, Gerss J, Wiebe S, Mikesch J-H, Knoblauch N, Sauer T, et al. A phase I dose escalation study of the triple Angiokinase inhibitor Nintedanib combined with low-dose Cytarabine in elderly patients with acute myeloid leukemia. PLoS One. 2016;11:e0164499.","journal-title":"PLoS One"},{"key":"999_CR36","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1385\/IR:23:2-3:263","volume":"23","author":"JE Ohm","year":"2001","unstructured":"Ohm JE, Carbone DP. VEGF as mediator of tumor-associated immunodeficiency. Immunol Res. 2001;23:263\u201372.","journal-title":"Immunol Res"},{"key":"999_CR37","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nri3064","volume":"11","author":"GT Motz","year":"2011","unstructured":"Motz GT, Coukos G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol. 2011;11:702\u201311.","journal-title":"Nat Rev Immunol"},{"key":"999_CR38","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3389\/fonc.2015.00202","volume":"5","author":"PA Ott","year":"2015","unstructured":"Ott PA, Hodi FS, Buchbinder EI. Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data. Front Oncol. 2015;5:202.","journal-title":"Front Oncol"},{"key":"999_CR39","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1096\/fj.14-250985","volume":"29","author":"H Huang","year":"2015","unstructured":"Huang H, Langenkamp E, Georganaki M, Loskog A, Fuchs PF, Dieterich LC, et al. VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-kB-induced endothelial activation. FASEB J. 2015;29:227\u201338.","journal-title":"FASEB J"},{"key":"999_CR40","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/cei.12069","volume":"172","author":"S Yasuda","year":"2013","unstructured":"Yasuda S, Sho M, Yamato I, Yoshiji H, Wakatsuki K, Nishiwada S, et al. Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumor effect in vivo. Clin Exp Immunol. 2013;172:500\u20136.","journal-title":"Clin Exp Immunol"},{"key":"999_CR41","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.20140559","volume":"212","author":"T Voron","year":"2015","unstructured":"Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, Pointet A-L, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med. 2015;212:139\u201348.","journal-title":"J Exp Med"},{"key":"999_CR42","first-page":"2514","volume":"6","author":"S Four Du","year":"2016","unstructured":"Du Four S, Maenhout SK, Niclou SP, Thielemans K, Neyns B, Aerts JL. Combined VEGFR and CTLA-4 blockade increases the antigen-presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs. Am J Cancer Res. 2016;6:2514\u201331.","journal-title":"Am J Cancer Res"},{"key":"999_CR43","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","volume":"24","author":"DF McDermott","year":"2018","unstructured":"McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018;24:749\u201357.","journal-title":"Nat Med"},{"key":"999_CR44","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nature13904","volume":"515","author":"T Powles","year":"2014","unstructured":"Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515:558\u201362.","journal-title":"Nature"},{"key":"999_CR45","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crin\u00f2 L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. New Engl J Med. 2015;373:123\u201335.","journal-title":"New Engl J Med"},{"key":"999_CR46","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. New Engl J Med. 2015;373:1803\u201313.","journal-title":"New Engl J Med."},{"key":"999_CR47","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. New Engl J Med. 2015;372:320\u201330.","journal-title":"New Engl J Med."},{"key":"999_CR48","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. New Engl J Med. 2016;375:1856\u201367.","journal-title":"New Engl J Med."},{"key":"999_CR49","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1634\/theoncologist.2015-0507","volume":"21","author":"D Kazandjian","year":"2016","unstructured":"Kazandjian D, Suzman DL, Blumenthal G, Mushti S, He K, Libeg M, et al. FDA approval summary: Nivolumab for the treatment of metastatic non-small cell lung Cancer with progression on or after platinum-based chemotherapy. Oncologist. 2016;21:634\u201342.","journal-title":"Oncologist"},{"key":"999_CR50","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1634\/theoncologist.2015-0498","volume":"21","author":"J Sul","year":"2016","unstructured":"Sul J, Blumenthal GM, Jiang X, He K, Keegan P, Pazdur R. FDA approval summary: Pembrolizumab for the treatment of patients with metastatic non-small cell lung Cancer whose tumors express programmed death-ligand 1. Oncologist. 2016;21:643\u201350.","journal-title":"Oncologist"},{"issue":"suppl 4S","key":"999_CR51","doi-asserted-by":"publisher","first-page":"abstract 2","DOI":"10.1200\/JCO.2017.35.4_suppl.2","volume":"35","author":"Y-K Kang","year":"2017","unstructured":"Kang Y-K, Satoh T, Ryu M-H, Chao Y, Kato K, Chung HC, et al. Nivolumab (ONO-4538\/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastroesophageal junction cancer (AGC): a double-blinded, randomized, phase III trial. J Clin Oncol. 2017;35(suppl 4S):abstract 2.","journal-title":"J Clin Oncol"},{"key":"999_CR52","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet. 2017;389:2492\u201302.","journal-title":"Lancet"},{"key":"999_CR53","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","volume":"2","author":"EA Mittendorf","year":"2014","unstructured":"Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. PD-L1 expression in triple-negative breast Cancer. Cancer Immunol Res. 2014;2:361\u201370.","journal-title":"Cancer Immunol Res"},{"key":"999_CR54","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/his.12904","volume":"69","author":"RK Beckers","year":"2016","unstructured":"Beckers RK, Selinger CI, Vilain R, Madore J, Wilmott JS, Harvey K, et al. Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and improved outcome. Histopathology. 2016;69:25\u201334.","journal-title":"Histopathology"},{"key":"999_CR55","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1158\/2326-6066.CIR-14-0133","volume":"3","author":"H Wimberly","year":"2015","unstructured":"Wimberly H, Brown JR, Schalper K, Haack H, Silver MR, Nixon C, et al. PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer. Cancer Immunol Res. 2015;3:326\u201332.","journal-title":"Cancer Immunol Res."},{"key":"999_CR56","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s10549-011-1554-7","volume":"132","author":"M Ono","year":"2012","unstructured":"Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H, et al. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 2012;132:793\u201305.","journal-title":"Breast Cancer Res Treat"},{"key":"999_CR57","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","volume":"31","author":"S Loi","year":"2013","unstructured":"Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31:860\u20137.","journal-title":"J Clin Oncol"},{"key":"999_CR58","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1038\/bjc.2013.634","volume":"109","author":"AN Seo","year":"2013","unstructured":"Seo AN, Lee HJ, Kim EJ, Kim HJ, Jang MH, Lee HE, et al. Tumor-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer. 2013;109:2705\u201313.","journal-title":"Br J Cancer"},{"key":"999_CR59","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1200\/JCO.2013.55.0491","volume":"32","author":"S Adams","year":"2014","unstructured":"Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32:2959\u201366.","journal-title":"J Clin Oncol"},{"key":"999_CR60","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.pathol.2016.10.010","volume":"49","author":"SJ Luen","year":"2017","unstructured":"Luen SJ, Savas P, Fox SB, Salgado R, Loi S. Tumor-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. Pathology. 2017;49:141\u201355.","journal-title":"Pathology"},{"key":"999_CR61","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","volume":"34","author":"R Nanda","year":"2016","unstructured":"Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 2016;34:2460\u20137.","journal-title":"J Clin Oncol"},{"key":"999_CR62","doi-asserted-by":"crossref","unstructured":"Emens LA, Braiteh FS, Cassier P, DeLord J-P, Eder JP, Shen X, et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9\u201313; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl): Abstract nr PD1\u20136.","DOI":"10.1158\/1538-7445.SABCS14-PD1-6"},{"key":"999_CR63","unstructured":"Roche Group Media relations (2 July 2018). Phase III IMpassion130 study showed Roche\u2019s Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer. \n                    https:\/\/www.roche.com\/dam\/jcr:a919b908-88f5-4a98-a4ed-26aa173b0e3b\/en\/20180702-MR-IMpassion130_EN.pdf"},{"key":"999_CR64","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1158\/2326-6066.CIR-14-0053","volume":"2","author":"FS Hodi","year":"2014","unstructured":"Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2014;2:632\u201342.","journal-title":"Cancer Immunol Res."},{"key":"999_CR65","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1158\/2326-6066.CIR-16-0084","volume":"4","author":"X Wu","year":"2016","unstructured":"Wu X, Giobbie-Hurder A, Liao X, Lawrence D, McDermott D, Zhou J, et al. VEGF neutralization plus CTLA-4 blockade alters soluble and cellular factors associated with enhancing lymphocyte infiltration and humoral recognition in melanoma. Cancer Immunol Res. 2016;4:858\u201368.","journal-title":"Cancer Immunol Res."},{"key":"999_CR66","doi-asserted-by":"publisher","first-page":"12624","DOI":"10.1038\/ncomms12624","volume":"7","author":"JJ Wallin","year":"2016","unstructured":"Wallin JJ, Bendell JC, Funke R, Sznol M, Korski K, Jones S, et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun. 2016;7:12624.","journal-title":"Nat Commun"},{"key":"999_CR67","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10456-017-9550-0","volume":"20","author":"T Kuusk","year":"2017","unstructured":"Kuusk T, Albiges L, Escudier B, Grivas N, Haanen J, Powles T, et al. Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer. Angiogenesis. 2017;20:205\u201315.","journal-title":"Angiogenesis"},{"key":"999_CR68","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.it.2016.04.010","volume":"37","author":"PE Hughes","year":"2016","unstructured":"Hughes PE, Caenepeel S, Wu LC. Targeted therapy and checkpoint immunotherapy combinations for the treatment of Cancer. Trends Immunol. 2016;37:462\u201376.","journal-title":"Trends Immunol"},{"key":"999_CR69","doi-asserted-by":"crossref","unstructured":"Lee C-H, Makker V, Rasco D, Taylor M, Dutcus C, Shumaker R, et al. A phase 1b\/2 trial of lenvatinib plus pembrolizumab in patients with renal cell carcinoma. Ann Oncol. 2017;28(suppl_5) Abstract 847O.","DOI":"10.1093\/annonc\/mdx371.002"},{"key":"999_CR70","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1470-2045(18)30081-0","volume":"19","author":"MB Atkins","year":"2018","unstructured":"Atkins MB, Plimack ER, Puzanov I, Fishman MN, McDermott DF, Cho DC, et al. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol. 2018;19:405\u201315.","journal-title":"Lancet Oncol"},{"key":"999_CR71","unstructured":"ClinicalTrials.gov\n                    \n                   [Internet]. National Library of Medicine. Identifier NCT02856425, Trial Of Pembrolizumab And Nintedanib (PEMBIB); 2016 Aug 4 [cited 2018 Nov 6]; [about 8 screens]. Available from: \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02856425?term=nintedanib+cancer +pembib&rank=1\n                    \n                  . Accessed 6 Nov 2018."},{"key":"999_CR72","doi-asserted-by":"crossref","unstructured":"Chowdhury S, McDermott DF, Voss MH, Hawkins RE, Aimone P, Voi M, Isabelle N, et al. A phase I\/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC), J Clin Oncol. 2017;35(suppl_15) Abstract 4506.","DOI":"10.1200\/JCO.2017.35.15_suppl.4506"},{"key":"999_CR73","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s40425-018-0420-0","volume":"6","author":"A Amin","year":"2018","unstructured":"Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, et al. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. J Immunother Cancer. 2018;6:109.","journal-title":"J Immunother Cancer"},{"key":"999_CR74","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1158\/0008-5472.CAN-12-4183","volume":"73","author":"E Guerin","year":"2013","unstructured":"Guerin E, Man S, Xu P, Kerbel RS. A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs. Cancer Res. 2013;73:2743\u20138.","journal-title":"Cancer Res"},{"key":"999_CR75","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10549-010-0788-0","volume":"121","author":"CH Barrios","year":"2010","unstructured":"Barrios CH, Liu MC, Lee SC, Vanlemmens L, Ferrero JM, Tabei T, et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat. 2010;121:121\u201331.","journal-title":"Breast Cancer Res Treat"},{"key":"999_CR76","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.1158\/0008-5472.CAN-05-4411","volume":"66","author":"R Munoz","year":"2006","unstructured":"Munoz R, Man S, Shaked Y, Lee CR, Wong J, Francia G, et al. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res. 2006;66:3386\u201301.","journal-title":"Cancer Res"},{"key":"999_CR77","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1126\/science.2108497","volume":"247","author":"BA Teicher","year":"1990","unstructured":"Teicher BA, Herman TS, Holden SA, Wang YY, Pfeffer MR, Crawford JW, et al. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science. 1990;247:1457\u201361.","journal-title":"Science"},{"key":"999_CR78","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ccr.2008.08.001","volume":"14","author":"Y Shaked","year":"2008","unstructured":"Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M, et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as Chemosensitizing agents. Cancer Cell. 2008;14:263\u201373.","journal-title":"Cancer Cell"},{"key":"999_CR79","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1158\/1535-7163.MCT-17-1091","volume":"17","author":"EA Kuczynski","year":"2018","unstructured":"Kuczynski EA, Krueger J, Chow A, Xu P, Man S, Sundaravadanam Y, et al. Impact of chemical-induced mutational load increase on immune checkpoint therapy in poorly responsive murine tumors. Mol Cancer Ther. 2018;17:869\u201382.","journal-title":"Mol Cancer Ther"},{"key":"999_CR80","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. New Engl J Med. 2018;378:2288\u201301.","journal-title":"New Engl J Med."},{"key":"999_CR81","first-page":"1011","volume":"2","author":"TJ Abrams","year":"2003","unstructured":"Abrams TJ, Murray LJ, Pesenti E, Holway VW, Colombo T, Lee LB, et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with \"standard of care\" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther. 2003;2:1011\u201321.","journal-title":"Mol Cancer Ther"},{"key":"999_CR82","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1517\/14656566.8.14.2359","volume":"8","author":"BI Rini","year":"2007","unstructured":"Rini BI. Sunitinib. Expert Opin Pharmacother. 2007;8:2359\u201369.","journal-title":"Expert Opin Pharmacother"},{"key":"999_CR83","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1158\/1078-0432.CCR-16-0738","volume":"23","author":"M Quintela-Fandino","year":"2017","unstructured":"Quintela-Fandino M, Lluch A, Manso L, Calvo I, Cortes J, Garc\u00eda-Saenz JA, et al. 18F-fluoromisonidazole PET and activity of neoadjuvant Nintedanib in early HER2-negative breast Cancer: a window-of-opportunity randomized trial. Clin Cancer Res. 2017;23:1432\u201341.","journal-title":"Clin Cancer Res"},{"key":"999_CR84","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/00000421-200010000-00007","volume":"23","author":"AW Tong","year":"2000","unstructured":"Tong AW, Seamour B, Lawson JM, Ordonez G, Vukelja S, Hyman W, et al. Cellular immune profile of patients with advanced cancer before and after taxane treatment. Am J Clin Oncol. 2000;23:463\u201372.","journal-title":"Am J Clin Oncol"},{"key":"999_CR85","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1158\/1078-0432.CCR-16-1433","volume":"23","author":"CS Lo","year":"2016","unstructured":"Lo CS, Sanii S, Kroeger DR, Milne K, Talhouk A, Chiu DS, et al. Neoadjuvant chemotherapy of ovarian Cancer results in three patterns of tumor-infiltrating lymphocyte response with distinct implications for immunotherapy. Clin Cancer Res. 2016;23:925\u201334.","journal-title":"Clin Cancer Res"},{"key":"999_CR86","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/sj.bjc.6600347","volume":"87","author":"N Tsavaris","year":"2002","unstructured":"Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer. 2002;87:21\u20137.","journal-title":"Br J Cancer"},{"key":"999_CR87","first-page":"3025","volume":"7","author":"S Demaria","year":"2001","unstructured":"Demaria S, Volm MD, Shapiro RL, Yee HT, Oratz R, Formenti SC, et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res. 2001;7:3025\u201330.","journal-title":"Clin Cancer Res"},{"key":"999_CR88","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.molimm.2007.08.013","volume":"45","author":"P Zhang","year":"2008","unstructured":"Zhang P, Su DM, Liang M, Fu J. Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. Mol Immunol. 2008;45:1470\u20136.","journal-title":"Mol Immunol"},{"key":"999_CR89","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1016\/j.humpath.2013.03.010","volume":"44","author":"A Cimino-Mathews","year":"2013","unstructured":"Cimino-Mathews A, Ye X, Meeker A, Argani P, Emens LA. Metastatic triple negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study. Hum Pathol. 2013;44:2055\u201363.","journal-title":"Hum Pathol"},{"key":"999_CR90","doi-asserted-by":"publisher","first-page":"103671","DOI":"10.18632\/oncotarget.22110","volume":"8","author":"R Ogiya","year":"2017","unstructured":"Ogiya R, Niikura N, Kumaki N, Yasojima H, Iwasa T, Kanbayashi C, et al. Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer. Oncotarget. 2017;8:103671\u201381.","journal-title":"Oncotarget"},{"key":"999_CR91","doi-asserted-by":"publisher","first-page":"e1075114","DOI":"10.1080\/2162402X.2015.1075114","volume":"5","author":"C Mall","year":"2015","unstructured":"Mall C, Sckisel GD, Proia DA, Mirsoian A, Grossenbacher SK, Pai CS, et al. Repeated PD-1\/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer. Oncoimmunology. 2015;5:e1075114.","journal-title":"Oncoimmunology"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-018-0999-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13046-018-0999-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-018-0999-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T19:08:08Z","timestamp":1578683288000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-018-0999-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,11]]},"references-count":91,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["999"],"URL":"https:\/\/doi.org\/10.1186\/s13046-018-0999-5","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,11]]},"assertion":[{"value":"29 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"FH works for Boehringer Ingelheim RCV, Vienna, Austria. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"16"}}